Conventional clinical trials are stadiums built from scratch for a single contest and dismantled the moment it ends, which accounts for much of what they cost and how long they take. Platform and basket trials replace that pattern with a standing arena, and when the structure stays up the arithmetic changes for arms, sponsors, sites, regulators, and above all, patients.

In this episode of "In the Interim…", Dr. Scott Berry recounts a presentation he gave to the Speak Foundation, a patient organization focused on limb-girdle muscular dystrophy and makes the case for master protocols directly to the stakeholder trials exist to serve.

In this episode of "In the Interim…", Dr. Scott Berry talks with Dr. Alun Bedding, a professional certified coach and statistician who spent decades in pharmaceutical statistics, including as global head of statistical methods, collaboration, and outreach at Roche, before founding his own coaching and consulting practice.

In this episode of “In the Interim…,” Dr. Scott Berry talks with Dr. Roger Lewis, Dr. Anna McGlothlin, and Dr. Nick Berry — all co-authors on the CHIPS trial results recently published in JAMA (Spinella et al., August 2026) — about the design, implementation, and results.

Berry Consultants is excited to share a short video highlighting members of our team and their planned presentations at the upcoming ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop (RISW) in Rockville, Maryland, September 16-18, 2026.

In this episode of "In the Interim…", Dr. Scott Berry examines three recent health-research headlines through a statistician's lens: an Adventist Health Study-2 analysis, an Emory University trial, and a British Medical Journal study.